drugset / Trial / NCT06413615
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressing/expressing solid tumors which are not eligible for curative therapy.
Timeline
- Start
- 2024-05-13
- Primary completion
- 2025-07-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FDA022-BB05 | Monoclonal antibody | 5.4 mg/kg | Intravenous |